The pharma 1.0 model of exclusively using data from clinical trials to justify the need for new drugs should be reviewed since the cost of collecting sufficient data is becoming uneconomic, the process denies early access to these new therapies and the data does not truly represent how they will work in the real world. 

We need a Pharma 2.0 model where new therapies are developed and evaluated collaboratively. However, to achieve this pharma must be willing to do things differently. It must be more transparent about sharing data and work in partnership with healthcare providers, governments, charities, plus other pharma companies, diagnostics companies and involved parties. 

The Salford Lung Study is one example of a “real world trial”; while Cancer Research UK’s Stratified Medicines Project also demonstrates that two pharma companies can work together with the UK government’s technology strategy board and a charity to evaluate the impact of genetics on new therapies – in this case for lung cancer.

For more information on M3, the global provider of technology services in healthcare, and its new European Division which includes,, and, please call Tim Ringrose on  +44 (0)1235 828400, or email .

You can read the full article on real-world data from the July/August issue of PharmaTimes Magazine that this comment appeared beside here.